Sponsors (18)
The bill creates a faster, clearer federal pathway for doctors to provide investigational Schedule I therapies to patients while improving regulatory certainty, but it increases risks of diversion and adds compliance and administrative costs that could limit participation and impose burdens on enforcement agencies.
Patients with serious or chronic conditions and the physicians who treat them gain a clear federal pathway to obtain, possess, and administer Schedule I investigational drugs, enabling legal access to experimental therapies that were previously unavailable or uncertain under federal law.
Patients and providers get faster, more predictable access because the law sets firm timelines for agency decisions (45 days for initial registrations; 30 days for supplemental approvals), which can reduce delays in starting investigational treatments.
Hospitals, institutional physicians, and multi-site practices can rely on a single registration to cover multiple related sites within the same city or county, lowering administrative overhead and simplifying institutional participation.
Patients and the public face increased risk of diversion, misuse, or accidental harm because the law expands routine federal authorization for possession and use of Schedule I drugs outside traditional tightly controlled research settings.
Physicians, clinics, and manufacturers may encounter significant new administrative and compliance burdens (applications, documentation, training, proof of state-law compliance) that could discourage participation and limit patient access in practice.
Deeming supplemental notifications approved after 30 days unless challenged could allow increases in possession or use before full federal review, weakening oversight and accountability for changes to authorized activities.
Based on analysis of 2 sections of legislative text.
Creates a DEA special registration that lets physicians directly administer Schedule I investigational drugs to eligible patients under federal right-to-try authority, with specific application and timeline rules.
Official title: To establish a special registration under the Controlled Substances Act for schedule I eligible investigational drugs under the Federal Right to Try law.
Introduced December 4, 2025 by Madeleine Dean · Last progress December 4, 2025
Creates a new DEA special registration pathway allowing physicians to obtain permission to directly administer Schedule I investigational drugs to eligible patients under existing federal "right to try" authority. It sets application requirements, limits on possession and sites, diversion-prevention documentation, and deadlines for agency action and rulemaking. Requires the Attorney General to grant or issue an order to show cause within 45 days of an application, permits electronic filings, allows one registration to cover multiple related sites in the same local area, and mandates an interim final rule within 240 days and a final rule within two years after the interim rule is issued.